Treating diabetes – benefit your influence by finding new R&D trends and sales prospects Discover the future of antidiabetic medicines. For those treatments, you will receive diabetes market size and revenue projections. You will learn the future potential by exploring research and development pipelines. And you will be able to assess results, trends, technologies, therapies and future business opportunities.
Visiongain’s updated report forecasts those revenues to 2026 at overall world market, submarket, product and national level. You can stay ahead with clear market data for treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.
See what’s possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines’ predicted revenue.
Forecasts to 2026 and other analyses explain and predict the diabetes treatment market Why miss crucial data that you need? Why struggle to find information? Instead our report gives you revenue forecasts to 2026, also with recent results, growth rates, market shares and discussions.
Our 258 page report provides 76 tables and 141 figures, and an interview with Professor Mark Baker, Director of the Centre for Clinical Practice (CCP) at the National Institute of Healthcare Excellence.
Our work’s purpose is to predict that industry’s future, helping your research, analyses and decisions. See how you can benefit your reputation for commercial insight, also helping your influence.
Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities exist.
The following sections show how our new investigation benefits your work.
Forecasting of the world diabetes drugs market and its segments – what does the future hold? What are the secrets of the industry’s progress? Where’s it heading? Discover in our report overall world revenue prediction to 2026 for antidiabetic pharmaceuticals, with discussions.
Also find individual revenue forecasts to 2026 for nine therapeutic submarkets at world level: • Human insulins and analogues • Dipeptidyl peptidase-4 inhibitors (DPP-4) • Biguanides • Glucagon-like peptide-1 receptor agonists (GLP-1) • Sulfonylureas.
And these treatment categories: • Thiazolidinediones • Alpha-glucosidase inhibitors • Meglitinides • Sodium-glucose co-transporter-2 inhibitors (SGLT2) • Other agents (grouped).
You can assess the outlook for revenue expansion, learning where you can profit. Find the diabetes market size from 2016-2026. You can investigate the competition and rising sales. And you will examine technological, clinical and commercial possibilities.
Also you will find top medicines’ revenue potentials.
Predictions of leading products’ sales – see what’s possible, and where you can gain How will individual drugs for elevated blood sugar perform to 2026 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents: • Lantus • Januvia • NovoLog and NovoMix • Levemir • Humalog • Victoza • Janumet • Humulin.
There you will find drugs and the years with highest predicted sales. You can also examine competitors. So discover what’s happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.
Our work also gives geographical sales predictions.
National markets – what is the outlook for treatment demand and revenues? In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2016 to 2026. See where, how and what’s possible.
Our analyses show you individual revenue forecasts to 2026 for 11 national markets: • United States (US) • Japan • EU leaders – Germany, France, the UK, Italy and Spain (EU5) • BRIC nations – Brazil, Russia, India and China.
There you can explore the market progress, needs and opportunities. What events will change that market and the outlook for payers and patients? Our work shows you, discussing the trends and demands.
Events affecting developers, producers and sellers of those metabolic treatments Our report also explains issues, forces and events affecting the antidiabetics industry and market from 2016, including these influences: • Drug approvals and R&D in human insulins and analogues, DPP-4 inhibition, GLP-1 therapies, sodium glucose co-transporter mechanisms and other candidates • Governmental investment and collaboration between pharmaceutical companies • Combination therapies for type 2 diabetes • Competition from biosimilars and generic drugs – approvals and product launches.
And these issues are also assessed, among others: • Disease incidence and prevalence • Risk factors – obesity and pre-diabetes, related metabolic conditions • Drug delivery – technologies for introducing insulin and oral drugs • New classes of antidiabetic medications and regulatory challenges • Type 1 diabetes vaccine – new treatment approaches, including disease prevention.
Diabetes management forms a leading use for biological drugs, now dominant in the pharmaceuticals industry. There you can investigate what stimulates and restrains that biopharma, affecting its results. Also you will see the prospects for small-molecule therapies.
Analysis of firms and potential for rising sales – what overall revenues are possible? What happens next? Our study predicts the world market will rise to $75bn in 2020, with high, expanding revenues from 2016 to 2026. Discover what’s possible.
Our analysis covers organisations shaping that industry: • Novo Nordisk • Eli Lilly • Novartis • AstraZeneca • Merck & Co.
We also investigate these leading companies, among other firms, including specialists in metabolic disorders: • Boehringer Ingelheim • Takeda • Sanofi • Bayer • Pfizer.
From 2016, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from those medications.
Ways Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2016-2026 helps In particular, our new investigation gives this knowledge to benefit your work: • Antidiabetic drug revenues to 2026 at overall world level, for 9 therapeutic submarkets and 31 products – assess outlooks for production, marketing and sales • Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia – investigate developed and developing countries for demand and revenue potentials • Prospects for established competitors, rising companies and new entrants – explore portfolios, opinions, results, strategies, technologies and outlooks for success • Review of R&D pipelines – examine progress in research and development, finding technological and medical prospects • Analysis of what stimulates and restrains that industry and market – gauge challenges and strengths, helping you compete, gain advantages and succeed.
Our new study, produced in-house by our UK-based analysts, helps your knowledge and authority.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Introduction to the Diabetes Industry and Market 1.2 Main Report Findings 1.3 This Study Provides the Following Knowledge 1.4 Why You Should Read This Report 1.5 How This Report Delivers 1.6 Main Questions Answered by This Study 1.7 Who is This Study For? 1.8 Research Methods and Analysis 1.9 Frequently Asked Questions (FAQ) 1.10 Associated Visiongain Reports 1.11 About Visiongain
2. Global Diabetes Drugs Market: Introduction 2.1 World Diabetes Drugs Market Segmentation 2.2 What is Diabetes? 2.3 How is Diabetes Classified? 2.4 Risk Factors, Disease Symptoms and Complications 2.5 Criteria for the Diagnosis of Diabetes 2.6 World and Regional Diabetes Incidence and Prevalence 2.7 The Economic Burden of Diabetes 2.8 Unmet Need 2.9 Leading Classes of Diabetic Medications 2.9.1 Type 1 Medication 2.9.1.1 Insulin 2.9.1.2 Surgical Options 2.9.2 Type 2 Medication 2.9.2.1 Alpha-glucosidase Inhibitors 2.9.2.2 Biguanides 2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2) 2.9.2.5 Thiazolidinediones 2.9.2.6 Sulfonylureas 2.9.2.7 Meglitinides 2.9.2.8 Other Injectable Medications 2.9.2.9 Combination Drug Therapies for Type 2 Diabetes
3. The World Diabetes Drugs Market, 2016-2026 3.1 The World Diabetes Drug Market, 2015 3.1.1 Diabetes Treatment Market by Drug Class, 2015 3.1.2 Top Selling Diabetes Drugs, 2015 3.1.3 Generic Anti-Diabetes Drugs, 2015 3.2 World Diabetes Drugs Market: Revenue Forecast, 2016-2026 3.3 Injectable and Non-injectable Diabetes Drugs, 2016-2026 3.3.1 Injectable Diabetes Drugs Revenue Forecast, 2016-2026 3.3.2 Non-Injectable Diabetes Drugs Revenue Forecast, 2016-2026
4. Human Insulin and Analogues, 2016-2026 4.1 Insulin and Insulin Analogues Drugs, 2015 4.2 Insulin and Insulin Analogues: Revenue Forecast, 2016-2026 4.3 Insulin and Insulin Analogues: Market Trends, 2016-2026 4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance? 4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming? 4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2016-2026 4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026 4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2016-2026 4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast, 2016-2026 4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2016-2026 4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026 4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2016-2026
13. National Markets for Diabetes Drugs, 2016-2026 13.1 Leading National Markets for Diabetes Drugs, 2015 13.2 Leading National Diabetes Drugs Market: Revenue Forecast, 2016-2026 13.3 The US to Sustain its Market Leadership: Revenue Forecast 2016-2026 13.3.1 High Diabetes Prevalence within a Complex Healthcare System 13.4 The Japanese Market, Revenue Forecast, 2016-2026 13.4.1 Sanofi and Takeda Collaborate to Fight Diabetes in Japan 13.4.2 Novel Treatment Options in Japan 13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2015 13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market Revenue Forecasts, 2016-2026 13.5.2 Germany: Disease Treatment Measures Require Improvement – Revenue Forecast, 2016-2026 13.5.2.1 Tough Reimbursement Rules: More Data for Faster Approval? 13.5.3 French National Diabetes Market Revenue Forecast, 2016-2026 13.5.3.1 Great Standard of Care and Regulatory Reforms in France 13.5.4 The UK National Diabetes Market Revenue Forecast, 2016-2026 13.5.4.1 Faster Approvals for New Therapies in the UK 13.5.5 Italian National Diabetes Market Revenue Forecast, 2016-2026 13.5.6 Spanish National Diabetes Market Revenue Forecast, 2016-2026 13.6 China: The World’s Largest Diabetic Population – Revenue Forecast, 2016-2026 13.6.1 Presence of Multinational Companies and the Power of Buyers 13.6.2 Disparity in Regional Health Spending 13.6.3 Multi-Billion Dollar Investment to Improve Healthcare 13.7 The Indian Market: Revenue Forecast, 2016-2026 13.7.1 Focus on the Rural Population 13.8 The Russian National Diabetes Market, 2016-2026 13.8.1 High Out of Pocket Costs Reduce Compliance 13.9 Brazil: Improved Access to Care in Rural Areas – Revenue Forecast, 2016-2026 13.9.1 Localised Insulin Production in Brazil 13.9.2 Diabetes Awareness Initiatives will Increase Market Potential
14. Diabetes Drug Market R&D Pipeline, 2016 14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015-2016 14.1.1 Novo Nordisk 14.1.2 Eli Lilly & Boehringer Ingelheim 14.1.3 AstraZeneca 14.2 Human Insulins and Analogues: New Approvals 14.2.1 Insulin Glargine (Basaglar, Eli Lilly and Boehringer Ingelheim): Receives US Approval After Delays 14.2.2 Insulin Glargine (Toujeo, Sanofi): Will it Replace Lantus? 14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin Fails to Make an Impact 14.3 Human Insulins and Analogues: Pipeline Developments: New Approvals 14.3.1 Tresiba (Novo Nordisk): Opportunity Revival 14.3.2 MK-1293 (Merck (MSD) and Biogen Idec): Will Provide more Biosimilar Competition for Lantus 14.3.3 NN9924 (Novo Nordisk) 14.3.4 BIOD-123 (Biodel) 14.4 DPP-4 Inhibitors: Pipeline Developments 14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex Pharmaceuticals): Approved in Japan 14.4.2 Omarigliptin (MK-3102; Merck (MSD)) 14.5 GLP-1: New Approvals and Pipeline, 2016 14.5.1 Trulicity (Dulaglutide; Eli Lilly): Potential for Blockbuster Status 14.5.2 Semaglutide (NN9535; Novo Nordisk) 14.5.3 Xultophy (IdegLira; Novo Nordisk) 14.5.4 ITCA 650 (Intarcia Theraputics) 14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2016 14.6.1 Sotagliflozin (Lexicon Pharmacuticals) 14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda) 14.6.3 MK8835 (Ertugliflozin; Merck (MSD)) 14.6.4 Bexagliflozin (Theracos) 14.7 Other Diabetes Drugs: Pipeline Developments, 2016 14.7.1 DM199 (DiaMedica) 14.7.2 Glucokinase Activators 14.7.2.1 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)
15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2016-2026 15.1 SWOT Analysis of the Diabetes Drug Market, 2016-2026 15.2 Strengths 15.2.1 Promising Research and Development 15.2.2 Secondary Indications 15.2.3 Biological Drugs are Tougher to copy and Offer Variety 15.2.4 Market Competition 15.3 Weaknesses 15.3.1 Lack of Disease Awareness 15.3.2 Tougher Reimbursement Rules 15.3.3 Increased Risk of Cardiovascular Complications 15.3.4 Rising Cost of Drug Development 15.4 Opportunities 15.4.1 Rising Disease Prevalence 15.4.2 Emerging National Markets Hold Great Potential 15.4.3 Novel Insulin Delivery Methods 15.4.4 New Classes of Anti Diabetes Drugs 15.5 Threats 15.5.1 Type 1 Diabetes Vaccine 15.5.2 Increased Popularity of Other Therapies 15.5.3 Generic Drugs: Patent Expiries and Rising Competition 15.5.4 Regulatory Barriers – Challenges Getting Drug Approval 15.6 STEP Analysis of the World Diabetes Drugs Market, 2016-2026 15.6.1 Social Developments 15.6.2 Technological Advances 15.6.3 Economic Factors 15.6.4 Political Issues
16. Research Interviews 16.1 Interview with Professor Mark Baker, Clinical Practice Director of the National Institute of Healthcare Excellence (NICE)
17. Conclusions from the Research and Analysis 17.1 The Diabetes Market – Trends Shaping Those Treatments 17.2 Outlook of the Worlds Diabetes Drug Industry, 2016-2026 17.3 Insulin Will Continue to Dominate the Market 17.4 National Diabetes Market Outlooks, 2016-2026 17.5 Future Opportunities
Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Report Evaluation Form
List of Tables Table 1.1 Leading National Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 2.1 Types of Injectable Insulin, 2016 Table 2.2 Oral Drug Classes for Type 2 Diabetes, 2016 Table 2.3 Other Injectable Drugs for Type 2 Diabetes, 2016 Table 2.4 Combination Drug Therapies for Type 2 Diabetes, 2016 Table 3.1 World Diabetes Drugs Market: Revenue ($m) and Market Share (%) by Type of Medication, 2015 Table 3.2 World Diabetes Drugs Market: Sales ($m) and Market Share (%) by Drugs Class, 2015 Table 3.3 Top 10 Diabetes Drugs Sales ($m), 2015 Table 3.4 World Diabetes Drugs Market: Revenue Forecasts ($m) by Drug Class, 2016-2026 Table 3.5 Injectable Diabetes Drugs: Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 3.6 Non-Injectable Diabetes Drugs: Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 4.1 Human Insulins and Analogues: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015 Table 4.2 Leading Human Insulin and Analogue Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 4.3 Top 3 Insulin Drug Producers: Insulin Portfolio, Sales ($m), and Insulin Submarket Share (%), 2015 Table 4.4 Lantus: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 4.5 NovoLog: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 4.6 Humalog: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 4.7 Levemir: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 4.8 Human Insulin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 4.9 NovoMix: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 4.10 Humulin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 5.1 DPP-4 Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015 Table 5.2 Leading DPP-4 Inhibitor Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 5.3 Januvia: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 5.4 Janumet: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 5.5 Galvus: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 5.6 Onglyza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 5.7 Nesina: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 5.8 Tradjenta: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 6.1 Sulfonylureas: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015 Table 6.2 Leading Sulfonylureas Drugs: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 6.3 Diamicron: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 6.4 Amaryl: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 6.5 Glucotrol: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 7.1 GLP-1: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015 Table 7.2 Leading GLP-1 Receptor Agonists: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 7.3 Victoza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 7.4 Byetta: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 7.5 Bydureon: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 8.1 Alpha-glucosidase Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015 Table 8.2 Leading Alpha-glucosidase Inhibitors: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 8.3 Glucobay: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 8.4 Basen: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 8.5 Glyset: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 9.1 Meglitinides: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015 Table 9.2 Leading Meglitinides: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 9.3 Prandin: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 9.4 Starlix: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 9.5 Glufast: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 10.1 Thiazolidinediones: Revenues ($m), 2015 Table 11.1 SGLT2 Inhibitors: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015 Table 11.2 Leading SGLT2 Inhibitors: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 11.3 Invokana: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 11.4 Forxiga: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 11.5 Jardiance: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 12.1 Biguanides: Producers, Revenues ($m) and Market Shares (%) for Leading Drugs, 2015 Table 12.2 Leading Biguanides: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 12.3 Glucophage: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 12.4 Glumetza: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 12.5 Fortamet: Drug Revenue Forecast ($m), AGR (%), CAGR (%), 2016-2026 Table 13.1 The Global Diabetes Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2015 Table 13.2 Leading National Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 13.3 The US: Drug Revenue Forecast ($m),Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.4 The Japan: Drug Revenue Forecast ($m),Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.5 EU5 (Germany, France, UK, Italy, Spain) Market: Revenue ($m), EU5 Market Share (%) and Global Market Share, 2015 Table 13.6 Leading National Diabetes Drugs Markets: Revenue Forecasts ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026 Table 13.7 Germany: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.8 France: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.9 The UK: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.10 Italy: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.11 Spain: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.12 China: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.13 India: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.14 Russia: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 13.15 Brazil: Drug Revenue Forecast ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 14.1 FDA Approvals for Anti Diabetes Drugs, 2015 and 2016
List of Figures Figure 2.1 Diabetes Drugs Market Segmentation Overview, 2016 Figure 2.2 Diabetes Drugs Market Segmentation Overview, 2016 Figure 2.3 Diabetes Types and Classification, 2016 Figure 2.4 Causes of Diabetes, 2016 Figure 2.5 Prevalence of Diabetes in Leading Economic Countries, 2015 Figure 3.1 World Diabetes Drugs Market: Market Share (%) by Type of Medication, 2015 Figure 3.2 World Diabetes Drugs Market: Market Shares (%) by Drug Class, 2015 Figure 3.3 Top 10 Diabetes Drugs by Market Share (%), 2015 Figure 3.4 World Diabetes Drugs Market: Revenue Forecast ($m), 2016-2026 Figure 3.5 World Diabetes Drugs Market: AGR Forecast (%), 2016-2026 Figure 3.6 Injectable Diabetes Drugs: Revenue Forecast ($m), 2016-2026 Figure 3.7 Injectable Diabetes Drugs: AGR Forecast (%), 2016-2026 Figure 3.8 Non-Injectable Diabetes Drugs: Revenue Forecast ($m), 2016-2026 Figure 3.9 Non-Injectable Diabetes Drugs: AGR Forecast (%), 2016-2026 Figure 4.1 Human Insulins and Analogues: Market Shares (%) for Leading Drugs, 2015 Figure 4.2 Insulin and Insulin Analogues Market: Revenue Forecast ($m), 2016-2026 Figure 4.3 Insulin and Insulin Analogues Market: AGR Forecast (%), 2016-2026 Figure 4.4 Lantus: Drug Revenue Forecast ($m), 2016-2026 Figure 4.5 Lantus: AGR Forecast (%), 2016-2026 Figure 4.6 NovoLog: Drug Revenue Forecast ($m), 2016-2026 Figure 4.7 NovoLog: AGR Forecast (%), 2016-2026 Figure 4.8 Humalog: Drug Revenue Forecast ($m), 2016-2026 Figure 4.9 Humalog: AGR Forecast (%), 2016-2026 Figure 4.10 Levemir: Drug Revenue Forecast ($m), 2016-2026 Figure 4.11 Levemir: AGR Forecast (%), 2016-2026 Figure 4.12 Human Insulins: Drug Revenue Forecast ($m), 2016-2026 Figure 4.13 Human Insulins: AGR Forecast (%), 2016-2026 Figure 4.14 NovoMix: Drug Revenue Forecast ($m), 2016-2026 Figure 4.15 NovoMix: AGR Forecast (%), 2016-2026 Figure 4.16 Humulin: Drug Revenue Forecast ($m), 2016-2026 Figure 4.17 Humulin: AGR Forecast (%), 2016-2026 Figure 5.1 DPP-4 Inhibitors: Market Shares (%) for Leading Drugs, 2015 Figure 5.2 DPP-4 Inhibitors: Sales ($m) for Leading Drugs, 2015 Figure 5.3 DPP-4 Inhibitor Drugs Market: Revenue Forecast ($m), 2016-2026 Figure 5.4 DPP-4 Inhibitor Drugs Market: AGR Forecast (%), 2016-2026 Figure 5.5 Januvia: Drug Revenue Forecast ($m), 2016-2026 Figure 5.6 Januvia: AGR Forecast (%), 2016-2026 Figure 5.7 Janumet: Drug Revenue Forecast ($m), 2016-2026 Figure 5.8 Janumet: AGR Forecast (%), 2016-2026 Figure 5.9 Galvus: Drug Revenue Forecast ($m), 2016-2026 Figure 5.10 Galvus: AGR Forecast (%), 2016-2026 Figure 5.11 Onglyza: Drug Revenue Forecast ($m), 2016-2026 Figure 5.12 Onglyza: AGR Forecast (%), 2016-2026 Figure 5.13 Nesina: Drug Revenue Forecast ($m), 2016-2026 Figure 5.14 Nesina: AGR Forecast (%), 2016-2026 Figure 5.15 Tradjenta: Drug Revenue Forecast ($m), 2016-2026 Figure 5.16 Tradjenta: AGR Forecast (%), 2016-2026 Figure 6.1 Sulfonylureas: Market Shares (%) for Leading Drugs, 2015 Figure 6.2 Sulfonylureas: Sales ($m) for Leading Drugs, 2015 Figure 6.3 Sulfonylureas: Drug Revenue Forecast ($m), 2016-2026 Figure 6.4 Sulfonylureas: AGR Forecast (%), 2016-2026 Figure 6.5 Diamicron: Drug Revenue Forecast ($m), 2016-2026 Figure 6.6 Diamicron: AGR Forecast (%), 2016-2026 Figure 6.7 Amaryl: Drug Revenue Forecast ($m), 2016-2026 Figure 6.8 Amaryl: AGR Forecast (%), 2016-2026 Figure 6.9 Glucotrol: Drug Revenue Forecast ($m), 2016-2026 Figure 6.10 Glucotrol: AGR Forecast (%), 2016-2026 Figure 7.1 GLP-1: Market Shares (%) for Leading Drugs, 2015 Figure 7.2 GLP-1: Revenue ($m) for Leading Drugs, 2015 Figure 7.3 GLP-1 Receptor Agonists: Revenue Forecast ($m), 2016-2026 Figure 7.4 GLP-1 Receptor Agonists: AGR Forecast (%), 2016-2026 Figure 7.5 Victoza: Drug Revenue Forecast ($m), 2016-2026 Figure 7.6 Victoza: AGR Forecast (%), 2016-2026 Figure 7.7 Byetta: Drug Revenue Forecast ($m), 2016-2026 Figure 7.8 Byetta: AGR Forecast (%), 2016-2026 Figure 7.9 Bydureon: Drug Revenue Forecast ($m), 2016-2026 Figure 7.10 Bydureon: AGR Forecast (%), 2016-2026 Figure 8.1 Alpha-glucosidase Inhibitors: Market Shares (%) for Leading Drugs, 2015 Figure 8.2 Alpha-glucosidase Inhibitors: Revenue Sales ($m), 2015 Figure 8.3 Alpha-glucosidase Inhibitors: Revenue Forecast ($m), 2016-2026 Figure 8.4 Alpha-glucosidase Inhibitors: AGR Forecast (%), 2016-2026 Figure 8.5 Glucobay: Drug Revenue Forecast ($m), 2016-2026 Figure 8.6 Glucobay: AGR Forecast (%), 2016-2026 Figure 8.7 Basen: Drug Revenue Forecast ($m), 2016-2026 Figure 8.8 Basen: AGR Forecast (%), 2016-2026 Figure 8.9 Glyset: Drug Revenue Forecast ($m), 2016-2026 Figure 8.10 Glyset: AGR Forecast (%), 2016-2026 Figure 9.1 Meglitinides: Market Shares (%) for Leading Drugs, 2015 Figure 9.2 Meglitinides: Market Sales ($m) for Leading Drugs, 2015 Figure 9.3 Meglitinides: Revenue Forecast ($m), 2016-2026 Figure 9.4 Meglitinides: AGR Forecast (%), 2016-2026 Figure 9.5 Prandin: Drug Revenue Forecast ($m), 2016-2026 Figure 9.6 Prandin: AGR Forecast (%), 2016-2026 Figure 9.7 Starlix: Drug Revenue Forecast ($m), 2016-2026 Figure 9.8 Starlix: AGR Forecast (%), 2016-2026 Figure 9.9 Glufast: Drug Revenue Forecast ($m), 2016-2026 Figure 9.10 Glufast: AGR Forecast (%), 2016-2026 Figure 10.1 Thiazolidinediones: Revenues ($m), 2015 Figure 11.1 SGLT2 Inhibitors: Market Share (%) for Leading Drugs, 2015 Figure 11.2 SGLT2 Inhibitors: Sales ($m) for Leading Drugs, 2015 Figure 11.3 SGLT2 Inhibitors: Revenue Forecast ($m), 2016-2026 Figure 11.4 SGLT2 Inhibitors: AGR Forecast (%), 2016-2026 Figure 11.5 Invokana: Drug Revenue Forecast ($m), 2016-2026 Figure 11.6 Invokana: AGR Forecast (%), 2016-2026 Figure 11.7 Forxiga: Drug Revenue Forecast ($m), 2016-2026 Figure 11.8 Forxiga: AGR Forecast (%), 2016-2026 Figure 11.9 Jardiance: Drug Revenue Forecast ($m), 2016-2026 Figure 11.10 Jardiance: AGR Forecast (%), 2016-2026 Figure 12.1 Biguanides: Market Shares (%) for Leading Drugs, 2015 Figure 12.2 Biguanides: Revenue ($m) for Leading Drugs, 2015 Figure 12.3 Biguanides: Revenue Forecast ($m), 2016-2026 Figure 12.4 Biguanides: AGR Forecast (%), 2016-2026 Figure 12.5 Glucophage: Drug Revenue Forecast ($m), 2016-2026 Figure 12.6 Glucophage: AGR Forecast (%), 2016-2026 Figure 12.7 Glumetza: Drug Revenue Forecast ($m), 2016-2026 Figure 12.8 Glumetza: AGR Forecast (%), 2016-2026 Figure 12.9 Fortamet: Drug Revenue Forecast ($m), 2016-2026 Figure 12.10 Fortamet: AGR Forecast (%), 2016-2026 Figure 13.1 The Global Diabetes Drugs Market: Revenues ($m) by Region, 2015 Figure 13.2 The Global Diabetes Drugs Market: Market Shares (%) by Region, 2015 Figure 13.3 The US Diabetes Drugs Market: Revenue Forecast ($m), 2016-2026 Figure 13.4 The US Diabetes Drugs Market: AGR Forecast (%), 2016-2026 Figure 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($m), 2016-2026 Figure 13.6 The Japanese Diabetes Drugs Market: AGR Forecast (%), 2016-2026 Figure 13.7 The EU5 (Germany, France, UK, Italy, Spain) Countries: Revenue ($m) by Country, 2015 Figure 13.8 EU5 (Germany, France, UK, Italy, Spain) Countries: EU5 Market Shares (%) by Country, 2015 Figure 13.9 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($m), 2016-2026 Figure 13.10 EU5 (Germany, France, UK, Italy, Spain): AGR Forecast (%), 2016-2026 Figure 13.11 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts by Country ($m), 2016-2026 Figure 13.12 Germany: Revenue Forecast ($m), 2016-2026 Figure 13.13 Germany: AGR Forecast (%), 2016-2026 Figure 13.14 France: Revenue Forecast ($m), 2016-2026 Figure 13.15 France: AGR Forecast (%), 2016-2026 Figure 13.16 UK: Revenue Forecast ($m), 2016-2026 Figure 13.17 UK: AGR Forecast (%), 2016-2026 Figure 13.18 Italy: Revenue Forecast ($m), 2016-2026 Figure 13.19 Italy: AGR Forecast (%), 2016-2026 Figure 13.20 Spain: Revenue Forecast ($m), 2016-2026 Figure 13.21 Spain: AGR Forecast (%), 2016-2026 Figure 13.22 China: Revenue Forecast ($m), 2016-2026 Figure 13.23 China: AGR Forecast (%), 2016-2026 Figure 13.24 India: Revenue Forecast ($m), 2016-2026 Figure 13.25 India: AGR Forecast (%), 2016-2026 Figure 13.26 Russia: Revenue Forecast ($m), 2016-2026 Figure 13.27 Russia: AGR Forecast (%), 2016-2026 Figure 13.28 Brazil: Revenue Forecast ($m), 2016-2026 Figure 13.29 Brazil: AGR Forecast (%), 2016-2026 Figure 15.1 SWOT Analysis of the World Diabetes Drugs Market, 2016-2026 Figure 15.2 STEP Analysis of the World Diabetes Drugs Market, 2016-2026 Figure 17.1 Revenue for the Main Diabetes Drugs Classes ($m), 2015, 2020 and 2026 Figure 17.2 Revenue for the Main National Diabetes Markets ($m), 2015, 2020 and 2026
Actavis Alphapharm American Diabetes Association Amylin Pharmaceuticals (acquired by Bristol Myers Squibb) Andromeda Biotech Arisaph Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil) Astellas Pharma AstraZeneca Bayer Biocon Blue Cross Bristol-Myers Squibb Biogen Idec Boehringer Ingelheim Boston Therapeutics Chugai Pharmaceutical Diabetes UK DiaMedica Diamyd Medical Eisai Eli Lilly European Medicines Agency (EMA) Express Scripts Food and Drug Administration (US FDA) Franco-Indian Pharmaceuticals Furiex Pharmaceuticals Genentech Generex Biotechnology Corporation GlaxoSmithKline (GSK) Glenmark Pharmaceuticals Google Human Genome Sciences Intarcia International Diabetes Federation (IDF) Janssen (subsidiary of J&J) Johnson & Johnson (J&J) Lupin Kissei Pharmaceuticals Kotobuki Pharma Kowa MannKind Corporation Mascot Health Series Merck & Co. Merck Serono Ministry of Health (MoH, Germany) Ministry of Health, Labour and Welfare (MHLW, Japan) MSD KK (Asian subsidiary of Merck & Co.) Mylan National Health Service (NHS, UK) National Institute of Health and Clinical Excellence (NICE, UK) Novartis Novo Nordisk Ono Pharmaceuticals Oramed Pharmaceuticals Patheon Pfizer Ranbaxy Laboratories Roche Salix Pharmaceuticals Sandoz Sanofi Santarus (bought by Salix Pharmaceuticals) Servier Shantha Biotechnics (acquired by Sanofi) Shionogi Pharmaceuticals Shreya Life Sciences Stanford University School of Medicine Sun Pharma Takeda Taisho Pharmaceutical Teva Pharmaceutical Industries Theracos Transdermal Specialities United States Diabetes Prevention Program (DPP) World Health Organization (WHO) Yabao Pharmaceutical Zydus Cadila
Download sample pages
Complete the form below to download your free sample pages for Diabetes World Drug Market Report 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Diabetes World Drug Market Report 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.
Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.
Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.
Visiongain Publishes Cell and Gene Supply Chain Services and Solutions Market Report 2020-2030
With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
